Pascual Sanz - Publications

Affiliations: 
Instituto de Biomedicina de Valencia, València, Comunidad Valenciana, Spain 

50 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Mollá B, Heredia M, Sanz P. Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model. Molecular Neurobiology. PMID 33447969 DOI: 10.1007/s12035-021-02285-1  0.36
2020 Perez-Jimenez E, Viana R, Muñoz-Ballester C, Vendrell-Tornero C, Moll-Diaz R, Garcia-Gimeno MA, Sanz P. Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease. Glia. PMID 33368637 DOI: 10.1002/glia.23956  0.8
2020 Aso E, Andrés-Benito P, Grau-Escolano J, Caltana L, Brusco A, Sanz P, Ferrer I. Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model. Cannabis and Cannabinoid Research. 5: 150-163. PMID 32656347 DOI: 10.1089/can.2019.0005  0.36
2020 Sanz P, Garcia-Gimeno MA. Reactive Glia Inflammatory Signaling Pathways and Epilepsy. International Journal of Molecular Sciences. 21. PMID 32521797 DOI: 10.3390/ijms21114096  0.8
2020 Gentry MS, Afawi Z, Armstrong DD, Delgado-Escueta A, Goldberg YP, Grossman TR, Guinovart JJ, Harris F, Hurley TD, Michelucci R, Minassian BA, Sanz P, Worby CA, Serratosa JM. The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic. Epilepsy & Behavior : E&B. 106839. PMID 31932179 DOI: 10.1016/J.Yebeh.2019.106839  0.4
2019 Sanchez-Martin P, Lahuerta M, Viana R, Knecht E, Sanz P. Regulation of the autophagic PI3KC3 complex by laforin/malin E3-ubiquitin ligase, two proteins involved in Lafora disease. Biochimica Et Biophysica Acta. Molecular Cell Research. 1867: 118613. PMID 31758957 DOI: 10.1016/j.bbamcr.2019.118613  0.8
2019 Muñoz-Ballester C, Santana N, Perez-Jimenez E, Viana R, Artigas F, Sanz P. In vivo glutamate clearance defects in a mouse model of Lafora disease. Experimental Neurology. 112959. PMID 31108086 DOI: 10.1016/j.expneurol.2019.112959  0.8
2018 Garcia-Gimeno MA, Rodilla-Ramirez PN, Viana R, Salas-Puig X, Brewer MK, Gentry MS, Sanz P. A novel EPM2A mutation yields a slow progression form of Lafora disease. Epilepsy Research. 145: 169-177. PMID 30041081 DOI: 10.1016/j.eplepsyres.2018.07.003  0.8
2018 Sanz P, Viana R, Garcia-Gimeno MA. AMPK Protein Interaction Analyses by Yeast Two-Hybrid. Methods in Molecular Biology (Clifton, N.J.). 1732: 143-157. PMID 29480473 DOI: 10.1007/978-1-4939-7598-3_9  0.8
2018 Rubio-Villena C, Viana R, Bonet J, Garcia-Gimeno MA, Casado M, Heredia M, Sanz P. Astrocytes: new players in progressive myoclonus epilepsy of Lafora type. Human Molecular Genetics. PMID 29408991 DOI: 10.1093/hmg/ddy044  0.8
2017 Qian J, García-Gimeno MA, Beullens M, Manzione MG, Van der Hoeven G, Igual JC, Heredia M, Sanz P, Gelens L, Bollen M. An Attachment-Independent Biochemical Timer of the Spindle Assembly Checkpoint. Molecular Cell. 68: 715-730.e5. PMID 29129638 DOI: 10.1016/j.molcel.2017.10.011  0.36
2017 López-González I, Viana R, Sanz P, Ferrer I. Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models. Molecular Neurobiology. 54: 3119-3130. PMID 27041370 DOI: 10.1007/s12035-016-9884-4  0.8
2016 Sanz P, Viana R, Garcia-Gimeno MA. AMPK in Yeast: The SNF1 (Sucrose Non-fermenting 1) Protein Kinase Complex. Experientia Supplementum (2012). 107: 353-374. PMID 27812987 DOI: 10.1007/978-3-319-43589-3_14  0.8
2016 Muñoz-Ballester C, Berthier A, Viana R, Sanz P. Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease. Biochimica Et Biophysica Acta. 1862: 1074-83. PMID 26976331 DOI: 10.1016/j.bbadis.2016.03.008  0.8
2016 Oligschlaeger Y, Miglianico M, Dahlmans V, Rubio-Villena C, Chanda D, García-Gimeno MA, Coumans WA, Liu Y, Voncken JW, Luiken JJ, Glatz JF, Sanz P, Neumann D. The interaction between AMPKβ2 and the PP1-targeting subunit R6 is dynamically regulated by intracellular glycogen content. The Biochemical Journal. PMID 26831516 DOI: 10.1042/BJ20151035  0.8
2015 Sánchez-Martín P, Romá-Mateo C, Viana R, Sanz P. Ubiquitin conjugating enzyme E2-N and sequestosome-1 (p62) are components of the ubiquitination process mediated by the malin-laforin E3-ubiquitin ligase complex. The International Journal of Biochemistry & Cell Biology. 69: 204-14. PMID 26546463 DOI: 10.1016/j.biocel.2015.10.030  0.8
2015 Viana R, Lujan P, Sanz P. The laforin/malin E3-ubiquitin ligase complex ubiquitinates pyruvate kinase M1/M2. Bmc Biochemistry. 16: 24. PMID 26493215 DOI: 10.1186/s12858-015-0053-6  0.8
2015 Rubio-Villena C, Sanz P, Garcia-Gimeno MA. Structure-Function Analysis of PPP1R3D, a Protein Phosphatase 1 Targeting Subunit, Reveals a Binding Motif for 14-3-3 Proteins which Regulates its Glycogenic Properties. Plos One. 10: e0131476. PMID 26114292 DOI: 10.1371/journal.pone.0131476  0.8
2015 Berthier A, Payá M, García-Cabrero AM, Ballester MI, Heredia M, Serratosa JM, Sánchez MP, Sanz P. Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease. Molecular Neurobiology. PMID 25627694 DOI: 10.1007/s12035-015-9091-8  0.56
2015 Raththagala M, Brewer MK, Parker MW, Sherwood AR, Wong BK, Hsu S, Bridges TM, Paasch BC, Hellman LM, Husodo S, Meekins DA, Taylor AO, Turner BD, Auger KD, Dukhande VV, ... ... Sanz P, et al. Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease. Molecular Cell. 57: 261-72. PMID 25544560 DOI: 10.1016/J.Molcel.2014.11.020  0.4
2013 Sanz P, Rubio T, Garcia-Gimeno MA. AMPKβ subunits: more than just a scaffold in the formation of AMPK complex. The Febs Journal. 280: 3723-33. PMID 23721051 DOI: 10.1111/febs.12364  0.8
2013 Rubio-Villena C, Garcia-Gimeno MA, Sanz P. Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is modulated by the laforin-malin complex. The International Journal of Biochemistry & Cell Biology. 45: 1479-88. PMID 23624058 DOI: 10.1016/j.biocel.2013.04.019  0.8
2013 Rubio T, Vernia S, Sanz P. Sumoylation of AMPKβ2 subunit enhances AMP-activated protein kinase activity. Molecular Biology of the Cell. 24: 1801-11, S1-4. PMID 23552691 DOI: 10.1091/mbc.E12-11-0806  0.6
2012 Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M, Sanz P. Glucose-dependent regulation of AMP-activated protein kinase in MIN6 beta cells is not affected by the protein kinase A pathway. Febs Letters. 586: 4241-7. PMID 23116618 DOI: 10.1016/j.febslet.2012.10.032  0.8
2012 Knecht E, Criado-García O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domínguez M, Navarro C, Serratosa JM, ... ... Sanz P, et al. Malin knockout mice support a primary role of autophagy in the pathogenesis of Lafora disease. Autophagy. 8: 701-3. PMID 22361617 DOI: 10.4161/auto.19522  0.6
2012 Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millán B, Heredia M, Romá-Mateo C, Mouron S, Juana-López L, Domínguez M, Navarro C, Serratosa JM, Sanchez M, ... Sanz P, et al. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Human Molecular Genetics. 21: 1521-33. PMID 22186026 DOI: 10.1093/hmg/ddr590  0.6
2011 Romá-Mateo C, Moreno D, Vernia S, Rubio T, Bridges TM, Gentry MS, Sanz P. Lafora disease E3-ubiquitin ligase malin is related to TRIM32 at both the phylogenetic and functional level. Bmc Evolutionary Biology. 11: 225. PMID 21798009 DOI: 10.1186/1471-2148-11-225  0.6
2011 Guerrero R, Vernia S, Sanz R, Abreu-Rodríguez I, Almaraz C, García-Hoyos M, Michelucci R, Tassinari CA, Riguzzi P, Nobile C, Sanz P, Serratosa JM, Gómez-Garre P. A PTG variant contributes to a milder phenotype in Lafora disease. Plos One. 6: e21294. PMID 21738631 DOI: 10.1371/journal.pone.0021294  0.6
2011 Couarch P, Vernia S, Gourfinkel-An I, Lesca G, Gataullina S, Fedirko E, Trouillard O, Depienne C, Dulac O, Steschenko D, Leguern E, Sanz P, Baulac S. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism. Journal of Molecular Medicine (Berlin, Germany). 89: 915-25. PMID 21505799 DOI: 10.1007/s00109-011-0758-y  0.6
2011 Vernia S, Heredia M, Criado O, Rodriguez de Cordoba S, Garcia-Roves PM, Cansell C, Denis R, Luquet S, Foufelle F, Ferre P, Sanz P. Laforin, a dual specificity phosphatase involved in Lafora disease, regulates insulin response and whole-body energy balance in mice. Human Molecular Genetics. 20: 2571-84. PMID 21493628 DOI: 10.1093/hmg/ddr157  0.6
2010 Knecht E, Aguado C, Sarkar S, Korolchuk VI, Criado-García O, Vernia S, Boya P, Sanz P, Rodríguez de Córdoba S, Rubinsztein DC. Impaired autophagy in Lafora disease. Autophagy. 6: 991-3. PMID 20818165 DOI: 10.4161/auto6.7.13308  0.6
2010 Garcia-Haro L, Garcia-Gimeno MA, Neumann D, Beullens M, Bollen M, Sanz P. The PP1-R6 protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 5080-91. PMID 20724523 DOI: 10.1096/fj.10-166306  0.8
2010 Moreno D, Towler MC, Hardie DG, Knecht E, Sanz P. The laforin-malin complex, involved in Lafora disease, promotes the incorporation of K63-linked ubiquitin chains into AMP-activated protein kinase beta subunits. Molecular Biology of the Cell. 21: 2578-88. PMID 20534808 DOI: 10.1091/mbc.E10-03-0227  0.56
2010 Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, Sanz P, de Córdoba SR, Knecht E, Rubinsztein DC. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Human Molecular Genetics. 19: 2867-76. PMID 20453062 DOI: 10.1093/hmg/ddq190  0.6
2009 Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, Rodriguez-Bada P, Colombo C, Lenzi L, Garcia-Gimeno MA, Bermudez-Silva FJ, Rodriguez de Fonseca F, Banin P, Aledo JC, Baixeras E, ... Sanz P, et al. Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. Molecular Endocrinology (Baltimore, Md.). 23: 1983-9. PMID 19884385 DOI: 10.1210/me.2009-0094  0.8
2009 Moreno D, Viana R, Sanz P. Two-hybrid analysis identifies PSMD11, a non-ATPase subunit of the proteasome, as a novel interaction partner of AMP-activated protein kinase. The International Journal of Biochemistry & Cell Biology. 41: 2431-9. PMID 19616115 DOI: 10.1016/j.biocel.2009.07.002  0.8
2009 Vernia S, Rubio T, Heredia M, Rodríguez de Córdoba S, Sanz P. Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. Plos One. 4: e5907. PMID 19529779 DOI: 10.1371/journal.pone.0005907  0.6
2009 Vernia S, Solaz-Fuster MC, Gimeno-Alcañiz JV, Rubio T, García-Haro L, Foretz M, de Córdoba SR, Sanz P. AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. The Journal of Biological Chemistry. 284: 8247-55. PMID 19171932 DOI: 10.1074/jbc.M808492200  0.6
2008 Moreno D, Knecht E, Viollet B, Sanz P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. Febs Letters. 582: 2650-4. PMID 18593584 DOI: 10.1016/j.febslet.2008.06.044  0.56
2008 Riera A, Ahuatzi D, Herrero P, Garcia-Gimeno MA, Sanz P, Moreno F. Human pancreatic beta-cell glucokinase: subcellular localization and glucose repression signalling function in the yeast cell. The Biochemical Journal. 415: 233-9. PMID 18588509 DOI: 10.1042/BJ20080797  0.8
2008 Viana R, Aguado C, Esteban I, Moreno D, Viollet B, Knecht E, Sanz P. Role of AMP-activated protein kinase in autophagy and proteasome function. Biochemical and Biophysical Research Communications. 369: 964-8. PMID 18328803 DOI: 10.1016/j.bbrc.2008.02.126  0.8
2008 Estalella I, Garcia-Gimeno MA, Marina A, Castaño L, Sanz P. Biochemical characterization of novel glucokinase mutations isolated from Spanish maturity-onset diabetes of the young (MODY2) patients. Journal of Human Genetics. 53: 460-6. PMID 18322640 DOI: 10.1007/s10038-008-0271-5  0.8
2007 Lesage B, Beullens M, Pedelini L, Garcia-Gimeno MA, Waelkens E, Sanz P, Bollen M. A complex of catalytically inactive protein phosphatase-1 sandwiched between Sds22 and inhibitor-3. Biochemistry. 46: 8909-19. PMID 17630778 DOI: 10.1021/bi7003119  0.8
2007 Viana R, Towler MC, Pan DA, Carling D, Viollet B, Hardie DG, Sanz P. A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits. The Journal of Biological Chemistry. 282: 16117-25. PMID 17403675 DOI: 10.1074/Jbc.M611804200  0.8
2007 Pedelini L, Marquina M, Ariño J, Casamayor A, Sanz L, Bollen M, Sanz P, Garcia-Gimeno MA. YPI1 and SDS22 proteins regulate the nuclear localization and function of yeast type 1 phosphatase Glc7. The Journal of Biological Chemistry. 282: 3282-92. PMID 17142459 DOI: 10.1074/jbc.M607171200  0.8
2006 Solaz-Fuster MC, Gimeno-Alcañiz JV, Casado M, Sanz P. TRIP6 transcriptional co-activator is a novel substrate of AMP-activated protein kinase. Cellular Signalling. 18: 1702-12. PMID 16624523 DOI: 10.1016/j.cellsig.2006.01.021  0.36
2005 Pedelini L, Garcia-Gimeno MA, Marina A, Gomez-Zumaquero JM, Rodriguez-Bada P, López-Enriquez S, Soriguer FC, Cuesta-Muñoz AL, Sanz P. Structure-function analysis of the alpha5 and the alpha13 helices of human glucokinase: description of two novel activating mutations. Protein Science : a Publication of the Protein Society. 14: 2080-6. PMID 15987895 DOI: 10.1110/ps.051485205  0.8
2005 Tomás-Cobos L, Viana R, Sanz P. TOR kinase pathway and 14-3-3 proteins regulate glucose-induced expression of HXT1, a yeast low-affinity glucose transporter. Yeast (Chichester, England). 22: 471-9. PMID 15849787 DOI: 10.1002/yea.1224  0.8
2004 Tomás-Cobos L, Casadomé L, Mas G, Sanz P, Posas F. Expression of the HXT1 low affinity glucose transporter requires the coordinated activities of the HOG and glucose signalling pathways. The Journal of Biological Chemistry. 279: 22010-9. PMID 15014083 DOI: 10.1074/jbc.M400609200  0.6
2002 Tomás-Cobos L, Sanz P. Active Snf1 protein kinase inhibits expression of the Saccharomyces cerevisiae HXT1 glucose transporter gene. The Biochemical Journal. 368: 657-63. PMID 12220226 DOI: 10.1042/BJ20020984  0.6
Show low-probability matches.